Pfizer says its antiviral pill slashes risk of severe Covid-19 by 89%
Skip to main content
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
  • More
    • Subscribe
    • Videos
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Games
    • Long Read
    • Interviews
    • Offbeat
    • Podcast
    • Quiz
    • Tech
    • Trial By Trivia
    • Magazine
  • বাংলা
The Business Standard

Tuesday
February 07, 2023

Sign In
Subscribe
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
  • More
    • Subscribe
    • Videos
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Games
    • Long Read
    • Interviews
    • Offbeat
    • Podcast
    • Quiz
    • Tech
    • Trial By Trivia
    • Magazine
  • বাংলা
TUESDAY, FEBRUARY 07, 2023
Pfizer says its antiviral pill slashes risk of severe Covid-19 by 89%

Coronavirus chronicle

Reuters
05 November, 2021, 05:15 pm
Last modified: 06 November, 2021, 11:15 am

Related News

  • US CDC still looking at potential stroke risk from Pfizer bivalent Covid shot
  • Pfizer/BioNTech's updated Covid shot shows strong response against BQ.1.1
  • European regulator recommends Pfizer's Omicron booster for children
  • Pfizer, BioNTech start Covid-flu combination vaccine study
  • Pfizer's RSV vaccine for pregnant women protects newborns against severe illness

Pfizer says its antiviral pill slashes risk of severe Covid-19 by 89%

The data has not yet been published or peer-reviewed, but Pfizer said in a news release that it would submit the data to regulators “as soon as possible

Reuters
05 November, 2021, 05:15 pm
Last modified: 06 November, 2021, 11:15 am
 A 3D printed Pfizer logo is placed near medicines from the same manufacturer in this illustration taken September 29, 2021. Photo :Reuters
A 3D printed Pfizer logo is placed near medicines from the same manufacturer in this illustration taken September 29, 2021. Photo :Reuters

* Trial stopped early after high success rate

* Results appear to surpass those of rival Merck drug

* Pfizer to submit interim data to FDA before Nov. 25 


Pfizer Inc's experimental antiviral pill to treat Covid-19 cut by 89% the chance of hospitalization or death for adults at risk of severe disease, the company said on Friday, as its CEO vowed to make this promising new weapon in the fight against the pandemic available globally as quickly as possible.

The trial's results suggest that Pfizer's drug surpasses Merck & Co Inc's pill, molnupiravir, which was shown last month to halve the chance of dying or being hospitalized for Covid-19 patients at high risk of serious illness.

Pfizer's pill, with the brand name Paxlovid, could secure US regulatory approval by the end of the year. Pfizer said it plans to submit interim trial results to the Food and Drug Administration (FDA) before the Nov. 25 US Thanksgiving holiday. The trial was stopped early due to its high success rate.

President Joe Biden said the US government has secured millions of doses of Pfizer's drug.

"If authorized by the FDA we may soon have pills that treat the virus in those who become infected," Biden said. "The therapy would be another tool in our toolbox to protect people from the worst outcomes of Covid."

Shares in Pfizer, which also makes one of the mostly widely used Covid-19 vaccines, rose 11% to close at $48.61. Merck's fell 10% to close at $81.61. Shares of vaccine makers took a hit, with Moderna Inc, Pfizer's German partner BioNTech SE and Novavax all down 11-21%.

Pfizer's pill is given in combination with an older antiviral called ritonavir. The treatment consists of three pills given twice daily. It has been in development for nearly two years.

The Pfizer and Merck pills are eagerly anticipated, with only limited options currently available for treating people sick with Covid-19. Full trial data is not yet available from either company.

Pfizer is in active discussions with 90 countries over supply contracts for its pill, Chief Executive Officer Albert Bourla said in an interview.

"Our goal is that everyone in the world would be able to have it as quickly as possible," Bourla said.

Bourla added that for high-income countries Pfizer expects to price its treatment close to where Merck has priced its drug. Merck's US contract price is around $700 for a five-day course of therapy. For low-income countries, Bourla said Pfizer is considering several options, with the goal of "no barrier for them as well to have access."

Merck's pill was approved by British regulator in a world first on Thursday.

Even with the potential offered by the Pfizer and Merck pills, preventing Covid-19 infections through broad use of vaccines remains the best way to control a pandemic that has killed more than 5 million people worldwide, including more than 750,000 in the United States, infectious disease experts said.

"Vaccines are going to be the most effective and reliable tool that we have in this pandemic," said Dr. Grace Lee, professor of pediatrics at Stanford University School of Medicine. "These oral medications are going to augment our ability to really reduce the risk of severe disease, hospitalization and death, which is huge, but it won't prevent infection."

While more than 7 billion vaccine doses have been administered worldwide, that has covered only about half the world's people. In the United States, 58% of all people, including 70% of adults, are fully vaccinated.

Mizuho analyst Vamil Divan forecast a "very minor impact" from Pfizer's drug on vaccination among people who do not want the vaccine or a booster shot as recommended by US health regulators.

"I think there's a small percentage of people that may decide not to get vaccinated now that there are good treatment options," Divan said.

MANUFACTURING GOALS

Pfizer said it expects to manufacture 180,000 treatment courses by the end of this year and at least 50 million courses by the end of next year, including 21 million in the first half of 2022. Bourla said that, based on the better-than-expected trial results, Pfizer is considering potentially doubling next year's manufacturing target.

Antivirals need to be given as early as possible, before an infection takes hold, to be most effective.

The planned analysis of 1,219 patients in Pfizer's study examined hospitalizations or deaths among people diagnosed with mild to moderate Covid-19 with at least one risk factor for developing severe disease, such as obesity or older age.

Among those given Pfizer's drug within three days of symptom onset, the pill lowered the chances of hospitalization or death for adults at risk of developing severe Covid-19 by 89% compared to those receiving a placebo. Among these patients, 0.8% were hospitalized and none died by 28 days after treatment, compared to a 7% hospitalization rate and seven deaths in the placebo group.

Rates were similar for patients treated within five days of symptoms: 1% of the treatment group was hospitalized, compared to 6.7% for the placebo group, which included 10 deaths. Pfizer said that represents 85% effectiveness at preventing hospitalization or death.

Two other trials - one in people without underlying risk factors and another in people who have been exposed to the virus but are not yet infected - are continuing, with those results likely be available in the first quarter of 2022, Bourla said.

Pfizer did not detail side any effects but said adverse events happened in about 20% of both treatment and placebo patients. Possible side effects include nausea and diarrhea.

Top News / World+Biz

Pfizer / Pfizer coronavirus vaccine / Pfizer Covid-19 Vaccine / Pfizer Inc

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Illustration: TBS
    Foreign aid for national budget drops by $1 billion: Finance Minister
  • Infographic: TBS
    FDI from US halves after sanctions
  • Photo: Mumit M
    RMG factories running below capacity due to less work orders: BGMEA chief

MOST VIEWED

  • Tourists ride a tour bus in Hong Kong, China October 25, 2019. REUTERS/Ammar Awad
    Hong Kong will give away half a million plane tickets. Here’s who can get them first
  • People wearing face masks following the coronavirus disease (Covid-19) outbreak are seen at Beijing Daxing International Airport in Beijing, China July 23, 2020. Photo:Reuters
    Pandemic to paradise: Chinese tourists return to Bali after three years
  • People walk outside wearing masks during the coronavirus disease (COVID-19) pandemic in the Harlem area of the Manhattan borough of New York City, New York, U.S., February 10, 2022. REUTERS/Carlo Allegri
    US to end Covid-19 emergency declarations on 11 May
  • A nurse prepares a shot for Jonathan Halter as the German embassy begins its roll out of BioNTech COVID-19 vaccines for German expatriates at a Beijing United Family hospital in Beijing, China January 5, 2023. REUTERS/Thomas Peter/File Photo
    Covid remains a public health emergency, says WHO
  • FIKE PHOTO: Medical staff moves a patient into a fever clinic at a hospital, as coronavirus disease (COVID-19) outbreaks continue in Shanghai, China, December 19, 2022. REUTERS/Aly Song
    China approves two domestically developed Covid drugs
  • People walk with their luggage at a railway station during the annual Spring Festival travel rush ahead of the Chinese Lunar New Year, as the coronavirus disease (COVID-19) outbreak continues, in Shanghai, China January 16, 2023. REUTERS/Aly Song
    Holiday trips within China surge after lifting of Covid curbs

Related News

  • US CDC still looking at potential stroke risk from Pfizer bivalent Covid shot
  • Pfizer/BioNTech's updated Covid shot shows strong response against BQ.1.1
  • European regulator recommends Pfizer's Omicron booster for children
  • Pfizer, BioNTech start Covid-flu combination vaccine study
  • Pfizer's RSV vaccine for pregnant women protects newborns against severe illness

Features

Nimah designed by Compass Architects- Wooden tiles. Photo: Junaid Hasan Pranto

Trendy flooring designs to upgrade any space

8h | Habitat
Benefits of having high ceilings in your new home

Benefits of having high ceilings in your new home

7h | Habitat
Each Reverse Osmosi plant can produce approximately 8,000 litres of drinking water a day for around 250 families. Photo: Sadiqur Rahman

A drop in the ocean of persistent water crisis

9h | Panorama
Photo: Collected

Get your partner a lovely present this Valentine's Day

1d | Brands

More Videos from TBS

30% companies see double-digit growth even in hard times

30% companies see double-digit growth even in hard times

11m | TBS Insight
Challenging time waiting for RMG

Challenging time waiting for RMG

7h | TBS Round Table
"Full Moon Meditation" organized by Department of Theater and Performance Studies, University of Dhaka

"Full Moon Meditation" organized by Department of Theater and Performance Studies, University of Dhaka

7h | TBS Graduates
10 cricketers who have played over 400 T20 matches

10 cricketers who have played over 400 T20 matches

7h | TBS SPORTS

Most Read

1
Photo: Courtesy
Panorama

From 'Made in Bangladesh' to 'Designed in Bangladesh'

2
Leepu realised his love for cars from a young age and for the last 40 years, he has transformed, designed and customised hundreds of cars. Photo: Collected
Panorama

'I am not crazy about cars anymore': Nizamuddin Awlia Leepu

3
Master plan for futuristic Chattogram city in the making
Districts

Master plan for futuristic Chattogram city in the making

4
The International Monetary Fund (IMF) logo is seen outside the headquarters building in Washington, U.S., September 4, 2018. REUTERS/Yuri Gripas/File Photo
Economy

IMF approves $4.7 billion loan for Bangladesh, calls for ambitious reforms

5
Belal Ahmed new acting chairman of SIBL
Banking

Belal Ahmed new acting chairman of SIBL

6
Photo: Collected
Crime

Prime Distribution MD Mamun arrested in fraud case

EMAIL US
[email protected]
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Privacy Policy
  • Comment Policy
Copyright © 2023
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - [email protected]

For advertisement- [email protected]